Vertex reports kidney drug trial results
Vertex Pharmaceuticals (NASDAQ:VRTX) reported positive Phase 2b AMPLIFIED study results for inaxaplin in people with APOL1-mediated kidney disease and different levels of proteinuria.
Vertex Pharmaceuticals (NASDAQ:VRTX) reported positive Phase 2b AMPLIFIED study results for inaxaplin in people with APOL1-mediated kidney disease and different levels of proteinuria.
Ionis Pharmaceuticals (NASDAQ:IONS) and Otsuka Pharmaceutical reported positive topline Phase 3 results for ulefnersen, an investigational RNA-targeted medicine for FUS-ALS.
Ligand Pharmaceuticals (NASDAQ:LGND) agreed to acquire royalty and milestone interests in Santen’s Ryjunea eye drop for a $23 million upfront payment.
Lexeo Therapeutics (NASDAQ:LXEO) agreed to acquire Mantle Therapeutics for up to $21.3 million to expand its Friedreich ataxia drug development portfolio.
GameStop (NYSE:GME) shares rose after CEO Ryan Cohen disclosed the purchase of approximately 1.15 million additional shares worth about $26.4 million.
MediWound (NASDAQ:MDWD) received an additional $3.3 million in non-dilutive funding to support development of a room-temperature-stable NexoBrid formulation for battlefield burn care.
Cognex Corporation (NASDAQ:CGNX) announced a definitive agreement to acquire RealSense, a provider of 3D robotic perception and depth-sensing camera technology, for approximately $500 million in cash.
Viking Therapeutics (NASDAQ:VKTX) announced positive topline results from a 33-week clinical study evaluating VK2735, its investigational GLP-1/GIP receptor agonist being developed for obesity treatment.
MillerKnoll (NASDAQ:MLKN) reported financial results for the first quarter of fiscal year 2027, showing improved profitability and order growth despite a decline in revenue.
AutoZone (NYSE:AZO) reported fourth-quarter and full fiscal year 2026 financial results, showing higher sales, improved profitability and continued expansion of its automotive aftermarket retail footprint.
GARANTA JÁ SEU GRAFA EDGE
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade